NERV logo

Minerva Neurosciences, Inc. Stock Price

NasdaqCM:NERV Community·US$204.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

NERV Share Price Performance

US$4.37
2.53 (137.50%)
US$4.37
2.53 (137.50%)
Price US$4.37

NERV Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk with imperfect balance sheet.

4 Risks
0 Rewards

Minerva Neurosciences, Inc. Key Details

US$0

Revenue

US$9.7m

Cost of Revenue

-US$9.7m

Gross Profit

US$405.4m

Other Expenses

-US$415.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-8.91
0%
0%
-24.1%
View Full Analysis

About NERV

Founded
2007
Employees
7
CEO
Remy Luthringer
WebsiteView website
www.minervaneurosciences.com

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Recent NERV News & Updates

Recent updates

No updates